Cancer Image Europe provides a robust, trustworthy platform for researchers, clinicians, and innovators to access diverse cancer images, enabling the benchmarking, testing, and piloting of AI-driven technologies.
By connecting high-quality cancer image data and AI experts, Cancer Image Europe facilitates collaboration and accelerates the development of cutting-edge solutions for cancer diagnosis and treatment.
EUCAIM aims to build a pan-European federated infrastructure for cancer images, connecting top cancer research institutions and making diverse cancer images available to researchers, clinicians, and innovators.
By providing access to a vast collection of cancer images, EUCAIM enables the development, benchmarking, testing, and piloting of AI-based technologies for cancer diagnosis and treatment.
EUCAIM seeks to enhance collaboration between cancer research institutions, AI experts, and industry stakeholders to accelerate the development of cutting-edge diagnostic and treatment solutions.
The ultimate objective of the EUCAIM project is to empower the next generation of cancer diagnostics and treatments, leading to improved patient outcomes and transforming cancer care across Europe.
To support research and development of new AI tools for cancer and ensure a seamless transition into clinical practice, we have divided our work plan into eight distinct work packages. These work packages cover diverse aspects such as data collection, infrastructure development, AI model evaluation, and dissemination, all of which are designed to facilitate effective collaboration, innovation, and the ultimate integration of these advancements into clinical practice across the cancer imaging ecosystem.
Explore our latest scientific publications, public deliverables and reports, and innovative online tools designed to advance cancer diagnostics and treatment.
Today, September 11th, 2024, our Scientific Coordinator took the spotlight at the EUCAIM and ESR webinar, “How to Advance Precision Medicine for Europe’s Cancer Patients
The CHAIMELEON Re-Identification Challenge, which aims to test the effectiveness of de-identification processes in AI-driven health projects, has extended its registration deadline to September 30, 2024.
Open Call applicants’ Guide to required legal and ethical documents: Table of Contents The EUCAIM open call was closed on the 10th of June. The
The EUCAIM consortium consist of 76 partners from 14 countries. Many partners are part of the “AI for Health Imaging” Network (AI4HI), a cluster of 5 large EU-funded projects on big data and AI in cancer imaging (CHAIMELEON, EUCANIMAGE, INCISIVE, ProCancer-I, PRIMAGE), whose data repositories EUCAIM is building on. The Consortium also involves major European Research Infrastructures, such as Euro-BioImaging, BBMRI, EATRIS and ELIXIR. Overall, in the EUCAIM consortium, public and private entities, many prestigious universities, private companies, and hospitals are represented to ensure that all of the necessary expertise are brought together for the success of EUCAIM.
We’re inviting new partners to enhance our pan-European infrastructure for cancer images and artificial intelligence.
Whether you’re a data holder with valuable cancer images or an innovator developing AI tools for precision medicine, this is your chance to contribute to a groundbreaking project.
Apply by 10 June 2024!
We recently hosted a webinar with more details for prospective applicants to the open call. A recording is available.
EUCAIM is looking for your feedback! We have recently published a Stakeholder Survey in order to reach out to potential end-users and stakeholders. We believe that your insights could significantly contribute to understanding the expectations of potential users and identifying the essential aspects that stakeholders find crucial for future engagement and collaboration with the platform.
Therefore, we would like to invite you to participate in the Stakeholder Survey about the Cancer Image Europe platform.
Completing the survey will take approximately 10 minutes. Your participation is crucial to the success of this project, and we deeply appreciate your expertise in shaping the future of cancer imaging and treatment.